Cat. No.: HY-N0512

Loganin

(Synonyms: Loganoside)

5 Cited Publications

Customer Review

Based on 5 publication(s) in Google Scholar

Loganin is a type of iridoid glycoside compound that possesses anti-inflammatory, antioxidant, and antitumor properties, and offers protective effects against acute lung injury and pulmonary fibrosis. Loganin exerts its protective effects against LPS (HY-D1056)-mediated inflammation and oxidative stress by upregulating the Nrf2/HO-1 signaling pathway, and it reduces neuroinflammation caused by spinal cord injury (SCI).

For research use only. We do not sell to patients.

Purity: 99.85%
CAS No.: 18524-94-2
Formula: C₁₇H₂₆O₁₀
Molecular Weight:390.38

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Loganin Chemical Structure

CAS No.: 18524-94-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	IC₅₀	1.28 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) Caco2 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay Cytotoxic activity against Homo sapiens (human) Caco2 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay	10.1007/s00044-011-9832-9
Caco-2	IC₅₀	3.45 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) Caco2 cells by clonogenic assay Cytotoxic activity against Homo sapiens (human) Caco2 cells by clonogenic assay	10.1007/s00044-011-9832-9
COLO 320	IC₅₀	1 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) COLO320 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay Cytotoxic activity against Homo sapiens (human) COLO320 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay	10.1007/s00044-011-9832-9
COLO 320	IC₅₀	2.2 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) COLO320 cells by clonogenic assay Cytotoxic activity against Homo sapiens (human) COLO320 cells by clonogenic assay	10.1007/s00044-011-9832-9
Huh-7	IC₅₀	16 μg/mL Compound: 5, ASB-00012351-010	Antiviral activity against HCV infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by NS5A staining Antiviral activity against HCV infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by NS5A staining	[PMID: 19904996]
MCF7	IC₅₀	4.85 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) MCF7 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay Cytotoxic activity against Homo sapiens (human) MCF7 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay	10.1007/s00044-011-9832-9
MCF7	IC₅₀	6.45 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) MCF7 cells by clonogenic assay Cytotoxic activity against Homo sapiens (human) MCF7 cells by clonogenic assay	10.1007/s00044-011-9832-9
PA-1	IC₅₀	1.45 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) PA1 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay Cytotoxic activity against Homo sapiens (human) PA1 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay	10.1007/s00044-011-9832-9
PA-1	IC₅₀	4.85 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) PA1 cells by clonogenic assay Cytotoxic activity against Homo sapiens (human) PA1 cells by clonogenic assay	10.1007/s00044-011-9832-9
WRL68	IC₅₀	1.86 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) WRL68 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay Cytotoxic activity against Homo sapiens (human) WRL68 cells incubated for 4 hr followed by compound wash-out measured after doubling time by MTT assay	10.1007/s00044-011-9832-9
WRL68	IC₅₀	3.2 μg/mL Compound: 1	Cytotoxic activity against Homo sapiens (human) WRL68 cells by clonogenic assay Cytotoxic activity against Homo sapiens (human) WRL68 cells by clonogenic assay	10.1007/s00044-011-9832-9

In Vitro

Loganin (0-50 µM; 24 h) shows significant cytotoxicity to RAW264.7 at high concentrations^[3].
Loganin (0-30 µM; 1 h) significantly reduces the production of NO, PGE2, TNF-α, and IL-1β in RAW264.7 macrophages stimulated by LPS (100 ng/ml, 24 h) in a dose-dependent manner, and increases the expression of Nrf2 and HO-1 in a concentration-dependent manner^[3].
Loganin (30 µM; 1 h) alleviates LPS-mediated ROS generation in RAW264.7 macrophages^[3].
Loganin (0-150 μg/mL; 48 h) reduces the survival rate, migration and invasion ability of Huh7 cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

RAW264.7 cells
Concentration:

0,5,10, 30 and 50 µM
Incubation Time:

24 h
Result:

Did not affect cytotoxicity at concentrations below 30 µM, but significant cytotoxicity was observed at 50 µM.

Western Blot Analysis^[6]

Cell Line:

Huh7 cells
Concentration:

0、50、100 and 150 μg/ml
Incubation Time:

48 h
Result:

Increased E-cadherin levels and decreased N-cadherin and vimentin levels in cells.

Western Blot Analysis^[3]

Cell Line:

RAW264.7 cells
Concentration:

0,5,10 and 30 µM
Incubation Time:

1 h
Result:

Significantly inhibited LPS-induced upregulation of iNOS and COX-2.
Compared with cells treated with loganin or LPS alone, Nrf2 protein expression was significantly upregulated in the nucleus of loganin-treated cells, but HO-1 expression was only observed in the cytoplasm.

In Vivo

Loganin (1-10 mg/kg; i.p.; once daily from day 1 to day 28 after SCI) dose-dependently reduced the degree of neurological damage in rats with SCI model^[4].
Loganin (80-200 mg/kg; i.g.; 8 weeks of Bleomycin induction, twice a week from week 4 (day 28)) concentration-dependently reduced BLM-induced lung injury in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Spinal cord injury rat model^[4]
Dosage:

1, 5 and 10 mg/kg
Administration:

i.p.; Administer once daily from 1 to 28 days after SCI
Result:

Improved the results of the inclined board test at a dose of 5 mg/kg on the 28th day after surgery and significantly improved the results of the inclined board test at a dose of 10 mg/kg from the 14th day after surgery.

Animal Model:

Bleomycin-induced pulmonary fibrosis model in mice^[5]
Dosage:

80、160 和 200 mg/kg
Administration:

i.g.; Bleomycin induction for 8 weeks, twice a week from the fourth week (day 28)
Result:

Improved alveolar structural destruction and interstitial inflammatory infiltration and reduced the hydroxyproline content in lung tissue.

Chemical Information

CAS No. 18524-94-2
Appearance Solid
Molecular Weight 390.38
Formula C₁₇H₂₆O₁₀
Color White to off-white
SMILES

O[C@H]([C@@H](O)[C@@H]1O)[C@](O[C@@H]1CO)([H])O[C@H]2[C@@]([C@H]3C)([H])[C@@](C[C@@H]3O)([H])C(C(OC)=O)=CO2
Synonyms

Loganoside
Structure Classification
- Terpenoids
- Iridoids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All Histological Imaging/StainingIFWB

Sort by:

Journal Impact Factor

PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Bioorg Chem

Discovery of cyanidin-3-O-galactoside as a novel CNT2 inhibitor for the treatment of hyperuricemia. [Abstract]

2024 Dec 30:154:108108. PMID: 39753042
Int J Cardiol

Loganin protects against myocardial ischemia-reperfusion injury by modulating oxidative stress and cellular apoptosis via activation of JAK2/STAT3 signaling. [Abstract]

2024 Jan 15:395:131426. PMID: 37813285

Loganin purchased from MedChemExpress. Usage Cited in: Int J Cardiol. 2024 Jan 15:395:131426. [Abstract]

Representative images of H&E staining showed that Loganin (20 mg/kg, i.p.)treatment prevented I/R-induced disorganization of cardiomyocytes, but administration of AG490 suppressed Loganin-induced enhancement of myocardial morphology.

Loganin purchased from MedChemExpress. Usage Cited in: Int J Cardiol. 2024 Jan 15:395:131426. [Abstract]

DHE signaling in ischemic heart tissue treated with Loganin (20 mg/kg, i.p.).

Loganin purchased from MedChemExpress. Usage Cited in: Int J Cardiol. 2024 Jan 15:395:131426. [Abstract]

Quantitative analysis showed that Loganin (20 mg/kg, i.p.)treatment prevented the I/Rinduced increase in the expression levels of caspase-3, caspase-9, and Bax in ischemic heart tissue and the I/R-induced decrease in the expression levels of Bcl-2.
J Stroke Cerebrovasc Dis

Loganin attenuates the inflammation, oxidative stress, and apoptosis through the JAK2/STAT3 pathway in cerebral ischemia-reperfusion injury. [Abstract]

2024 Nov 11:108114. PMID: 39537043
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (128.08 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5616 mL

12.8080 mL

25.6161 mL

5 mM

0.5123 mL

2.5616 mL

5.1232 mL

10 mM

0.2562 mL

1.2808 mL

2.5616 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kim MJ, et al. Loganin protects against pancreatitis by inhibiting NF-κB activation. Eur J Pharmacol. 2015 Oct 15;765:541-50. [Content Brief]

[2]. Tsai WH, et al. Ba-Wei-Di-Huang-Wan through its active ingredient loganin counteracts substance P-enhanced NF-κB/ICAM-1 signaling in rats with bladder hyperactivity. Neurourol Urodyn. 2015 Aug 19. [Content Brief]

[3]. Park C, et al. Loganin Inhibits Lipopolysaccharide-Induced Inflammation and Oxidative Response through the Activation of the Nrf2/HO-1 Signaling Pathway in RAW264.7 Macrophages. Biol Pharm Bull. [Content Brief]

[4]. Huang X, et al. Loganin reduces neuroinflammation and promotes functional recovery after spinal cord injury through inhibiting NF-κB/NLRP3 signalling. Toxicon. 2023 Aug 15;232:107202. [Content Brief]

[5]. Chen L, et al. Protective effect and mechanism of loganin and morroniside on acute lung injury and pulmonary fibrosis. Phytomedicine. 2022 May;99:154030. [Content Brief]

[6]. CHEN, et al. Loganin inhibits Liver Cancer Cell Proliferation and Metastasis via Blocking Mitogen-Activated Protein Kinase Signaling Pathway. Indian Journal of Pharmaceutical Sciences 86.1 (2024).

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5616 mL	12.8080 mL	25.6161 mL	64.0402 mL
	5 mM	0.5123 mL	2.5616 mL	5.1232 mL	12.8080 mL
	10 mM	0.2562 mL	1.2808 mL	2.5616 mL	6.4040 mL
	15 mM	0.1708 mL	0.8539 mL	1.7077 mL	4.2693 mL
	20 mM	0.1281 mL	0.6404 mL	1.2808 mL	3.2020 mL
	25 mM	0.1025 mL	0.5123 mL	1.0246 mL	2.5616 mL
	30 mM	0.0854 mL	0.4269 mL	0.8539 mL	2.1347 mL
	40 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6010 mL
	50 mM	0.0512 mL	0.2562 mL	0.5123 mL	1.2808 mL
	60 mM	0.0427 mL	0.2135 mL	0.4269 mL	1.0673 mL
	80 mM	0.0320 mL	0.1601 mL	0.3202 mL	0.8005 mL
	100 mM	0.0256 mL	0.1281 mL	0.2562 mL	0.6404 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Loganin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Loganin

All TNF Receptor Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Publications (5)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Loganin Related Classifications

Cat. No.: HY-N0512